Short Interest in Aprea Therapeutics, Inc. (NASDAQ:APRE) Declines By 46.6%
by Tristan Rich · The Markets DailyAprea Therapeutics, Inc. (NASDAQ:APRE – Get Free Report) was the target of a large decline in short interest in the month of June. As of June 15th, there was short interest totaling 63,530 shares, a decline of 46.6% from the May 31st total of 119,012 shares. Approximately 0.6% of the shares of the company are short sold. Based on an average daily trading volume, of 126,040 shares, the days-to-cover ratio is currently 0.5 days.
Institutional Trading of Aprea Therapeutics
Institutional investors have recently bought and sold shares of the business. AIGH Capital Management LLC raised its stake in shares of Aprea Therapeutics by 174.1% during the 1st quarter. AIGH Capital Management LLC now owns 1,015,541 shares of the company’s stock worth $775,000 after buying an additional 645,000 shares during the period. DRW Securities LLC acquired a new stake in Aprea Therapeutics in the 4th quarter valued at $103,000. Finally, Jane Street Group LLC acquired a new stake in Aprea Therapeutics in the 4th quarter valued at $40,000. 34.19% of the stock is owned by institutional investors and hedge funds.
Aprea Therapeutics Trading Down 0.0%
APRE traded down $0.00 on Thursday, reaching $0.74. The stock had a trading volume of 2,262 shares, compared to its average volume of 1,235,824. Aprea Therapeutics has a 12-month low of $0.55 and a 12-month high of $2.22. The business’s 50-day moving average price is $0.83 and its two-hundred day moving average price is $0.82. The company has a market cap of $9.22 million, a P/E ratio of -0.48 and a beta of 1.49.
Aprea Therapeutics (NASDAQ:APRE – Get Free Report) last issued its quarterly earnings data on Wednesday, May 13th. The company reported ($0.22) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.23) by $0.01. Aprea Therapeutics had a negative net margin of 4,405.59% and a negative return on equity of 61.03%. As a group, analysts predict that Aprea Therapeutics will post -0.84 earnings per share for the current year.
Analysts Set New Price Targets
A number of analysts have recently commented on APRE shares. HC Wainwright lowered their target price on Aprea Therapeutics from $4.00 to $1.20 and set a “buy” rating on the stock in a research note on Tuesday, March 31st. Wedbush reduced their price target on Aprea Therapeutics from $7.00 to $6.00 and set an “outperform” rating for the company in a research report on Thursday, May 14th. Weiss Ratings reissued a “sell (e+)” rating on shares of Aprea Therapeutics in a report on Monday, April 20th. Finally, Oppenheimer initiated coverage on Aprea Therapeutics in a research report on Thursday, May 7th. They issued an “outperform” rating and a $5.00 price objective on the stock. Three investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Hold” and an average target price of $4.07.
Get Our Latest Report on Aprea Therapeutics
Aprea Therapeutics Company Profile
Aprea Therapeutics is a clinical‐stage biopharmaceutical company dedicated to developing targeted therapies that restore tumor suppressor function in cancers driven by TP53 mutations. The company’s lead investigational agent, eprenetapopt (APR-246), is designed to convert mutant p53 protein into a form that induces programmed cell death in malignant cells. Aprea’s research focuses on hematologic malignancies, including myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML), as well as solid tumors harboring TP53 mutations.
Eprenetapopt has advanced through multiple clinical trials, including pivotal studies assessing its efficacy in combination with hypomethylating agents for patients with MDS.